As BIO2008 begins to wind down I finally have a few moments to catch my breath and rummage through the trendy conference bag and contents (BTW…next year would be very cool to have a wheeled conference bag with telescoping handle). I was flipping through the complimentary April/May ’08 copy of The Journal of Life Sciences (FYI…you can sign-up for a free subscription (HERE)). Just when a guy thinks he has rung out as much Colorado news and information from BIO2008, BANG! There is an article on Broomfield, CO-based Accera.
Accera is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company’s lead candidate, Ketasyn™ (AC-1202), is a first-in-class molecule that has completed successful clinical trials for Alzheimer’s disease and age-associated memory impairment. Accera plans to self-commercialize Ketasyn as a prescription-only therapeutic product for the treatment of Alzheimer’s in the US in 4Q08. A key element of Accera’s strategy is work with corporate partners to commercialize Ketasyn in non-U.S. markets, and to develop AC-1202 and other proprietary small molecule compounds in its pipeline for a range of neurodegenerative diseases. Learn more about the company (HERE).
Note: Take a closer look at what is transpiring in Colorado Bioscience at
- The Colorado Bioscience Association (HERE)
- The Colorado Science + Technolog Park @ Fitzsimons (HERE)